The Franco-Austrian laboratory Valneva plans to deliver the first doses of its vaccine against Covid-19 in Europe in the second quarter of 2022, the company said in a press release published on Friday.
Read alsoValneva sees its sales triple in 2021 thanks to its Covid vaccine candidate
Valneva's inactivated and adjuvanted vaccine against Covid, "
VLA2001
", is currently being scrutinized by the Committee for Medicinal Products for Human Use (CHMP), which sent the laboratory some additional questions regarding its serum at the end of February.
"
Valneva now expects to receive a positive recommendation from the CHMP for conditional authorization of VLA2001 for primary vaccination in adults aged 18-55 in April 2022
," the company said in a statement.
“
After this conditional clearance, the company is expected to begin delivering planned doses of VLA2001 to European countries in the second quarter of 2022
,” she said.
Read alsoCovid-19: the number of new contaminations is on the rise again
An agreement with the European Commission
The laboratory indicates that it has signed an agreement with the European Commission "
for the supply of a maximum of 60 million doses
" over two years, including 24.3 in 2022. Valneva has already received an authorization for the emergency use of his vaccine to the Kingdom of Bahrain, which bought him a million doses.
These will start shipping in March.
On the other hand, the United Kingdom terminated in September a contract relating to 100 million doses of this candidate vaccine.
VLA2001 is “
currently the only inactivated and adjuvanted vaccine candidate against Covid-19 in clinical development in Europe
”, underlines Valneva.
